Reimbursement Claims Analysis of Outcomes with Carvedilol and Metoprolol

No abstract is available for this paper.

• Publication year

  2002

• Venue

  The Annals of Pharmacotherapy

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1345/aph.1A146PMID 11895048
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heart failure disease management programs: efficacy and limitations.

  2001cited by this paper
• Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.

  2001cited by this paper
• Dynamics in drug coverage of Medicare beneficiaries: finders, losers, switchers.

  2001cited by this paper
• Cost-Effectiveness Results from the US Carvedilol Heart Failure Trials Program

  2001cited by this paper
• A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation.

  2000cited by this paper
• Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.

  2000cited by this paper
• The economic burden of heart failure

  2000cited by this paper
• beta-adrenergic receptor blockade in chronic heart failure.

  2000cited by this paper
• β-Adrenergic Receptor Blockade in Chronic Heart Failure

  2000cited by this paper
• THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE

  2000cited by this paper
• Overall cardiovascular profile of sildenafil citrate.

  1999cited by this paper
• Cost effectiveness of carvedilol for heart failure.

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• Beta-blockade in heart failure: a comparison of carvedilol with metoprolol.

  1999cited by this paper
• A COST MINIMISATION ANALYSIS OF CARDIAC FAILURE TREATMENT IN THE UK USING CIBIS TRIAL DATA

  1999cited by this paper
• Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches.

  1999cited by this paper
• Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Consensus recommendations for the management of chronic heart failure: Introduction

  1999cited by this paper
• Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure.

  1999cited by this paper
• Health economic consequences of the pharmacological treatment of heart failure.

  1998cited by this paper
• Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.

  1998cited by this paper
• CONGESTIVE HEART FAILURE IN OLDER ADULTS * : Epidemiology, Pathophysiology, and Etiology of Congestive Heart Failure in Older Adults

  1997cited by this paper
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Economic impact of heart failure in the United States: time for a different approach.

  1994cited by this paper
• Influence of Prerandomization (Baseline) Variables on Mortalit and on the Reduction of Mortalit by Enalapril Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V‐HeFT II)

  1993cited by this paper
• Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.

  1993cited by this paper
• Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

  1992cited by this paper
• Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.

  1992cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper

• How well do diagnosis-related groups for appendectomy explain variations in resource use? An analysis of patient-level data from 10 European countries.

  2012cites this paper
• Carvedilol

  2012cites this paper
• The effect of neurohormonal antagonists in reducing heart failure hospitalizations

  2006cites this paper
• Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.

  2005cites this paper